Disrupting the Paradigm: Partnering With Oncogene-Focused Patient Groups to Propel Research
Upal Basu RoyGenomic alterations drive more than 60% of adenocarcinoma cases of NSCLC.1 Approximately 25% of these cases will have an oncogenic driver (EGFR, ALK, ROS1, BRAF, or NTRK) that can be […] Read more
Posted: April 16, 2020 Read more
Posted: April 16, 2020 Read more
By Kim L. Sandler, MD, Melinda C. Aldrich, MPH, PhD, and Jeffrey D. Blume, PhD Posted: April 16, 2020 IN REFERENCE TO: Aldrich MC, Mercaldo SF, Sandler KL, Blot WJ, […] Read more
By Nathan Pennell, MD, PhD Posted: April 16, 2020 It’s an exciting time to be a thoracic oncologist. We live in an era of unprecedented discovery in medicine—and in oncology […] Read more
Stunning Progress Achieved in Lung Cancer Treatment Over the Last Decade
By Kara Nyberg, PhD Posted: April 16, 2020 After decades of failed clinical trials and persistently dismal lung cancer survival outcomes, the 2010s breathed new life into the beleaguered field […] Read more
By Jin Mo Goo, MD, PhD, and Yeol Kim, MD, MPH, PhD Posted: April 16, 2020 Dr. Jin Mo Goo Dr. Yeol Kim […] Read more
Liquid Biopsy’s Role in Marker Identification: An Interview With Dr. Martin Filipits
Posted: April 16, 2020 As we know, molecular marker identification allows for more rational use of existing therapies. When markers can be identified more effectively and quickly, patient care advances. […] Read more
Artificial Intelligence in Lung Cancer: Opening New Avenues for Detection, Diagnosis, and Prognostication
By Mizuki Nishino, MD, MPH Posted: April 16, 2020 Dr. Mizuki Nishino Artificial intelligence (AI) approaches have emerged as promising tools to address important unmet needs across different specialties in […] Read more
PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee
By Sylvie Lantuejoul, MD, PhD, and Mari Mino-Kenudson, MD Posted: April 16, 2020 Immune checkpoint inhibitors (ICI), which target the PD-1/PD-L1 axis with the aim of restoring anti-tumor immunity, are […] Read more